Stockreport
Comprehensive Diabetic Neuropathy Pipeline Insight Report for 2024 Reveals Progress in Treatment Landscape [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
An in-depth pipeline insight report has been released, offering a comprehensive overview of the ongoing research and development of treatments for Diabetic Neuropathy. The report delves into detailed profiles of therapeutics currently under clinical and nonclinical stages, assessing over 20 companies and 25 pipeline drugs. Understanding Diabetic Neuropathy Diabetic Neuropathy, a nerve damage condition associated with diabetes, presents a significant challenge due to its complex symptoms that affect millions worldwide. The report aims to furnish a thorough understanding of the disease, its symptoms, causes, and current treatment approaches. Emphasizing the importance of innovation in therapeutic development, the insight highlights novel drug candidates and their potential to transform the treatment landscape of Diabetic Neuropathy. Emerging Therapeutic Drugs and Therapeutic Assessment Key sections of the report offer a scrutinizing look at emerging drugs, providing analyses of
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Oncolytic Viruses: Unlocking a New Era in Cancer Immunotherapy | DelveInsight [Yahoo! Finance][Yahoo! Finance]
- Trends in biopharma: the future of manufacturing [Yahoo! Finance][Yahoo! Finance]
- Global Muscle Relaxant Drugs Market Size To Worth USD 5.91 Billion By 2033 | CAGR Of 4.24% [Yahoo! Finance][Yahoo! Finance]
- 1 Dividend Growth Stock to Buy and Hold for 10 Years [Yahoo! Finance][Yahoo! Finance]
- Coherus offloads Humira biosimilar Yusimry for $40m [Yahoo! Finance][Yahoo! Finance]
- More
AMGN
SEC Filings
SEC Filings
- 6/21/24 - Form 11-K
- 6/21/24 - Form 11-K
- 6/12/24 - Form S-8
- AMGN's page on the SEC website
- More